Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Quanterix Corporation - Common Stock (NQ:QTRX)

6.690 +0.040 (+0.60%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Quanterix Corporation - Common Stock

< Previous 1 2 3 4 5 6 Next >
Quanterix Corporation Releases Operating Results for Third Quarter 2022
From Quanterix Corporation
Via Business Wire
Quanterix’ Third Quarter 2022 Earnings Conference Call
From Quanterix Corporation
Via Business Wire
Quanterix Announces the Resignation of Kevin Hrusovsky as Executive Chairman of Board of Directors
From Quanterix Corporation
Via Business Wire
Quanterix Corporation Releases Operating Results for Second Quarter 2022, Announces Business Re-Alignment Plan and Revises 2022 Guidance
From Quanterix Corporation
Via Business Wire
Quanterix to Participate in the Canaccord Genuity 42nd Annual Growth Conference
From Quanterix Corporation
Via Business Wire
Quanterix’ Second Quarter 2022 Earnings Conference Call
From Quanterix Corporation
Via Business Wire
Quanterix Launches First pTau-181 Plasma Laboratory Developed Test for Clinical Diagnostic and Research Applications in the U.S.
From Quanterix Corporation
Via Business Wire
Quanterix to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference
From Quanterix Corporation
Via Business Wire
Quanterix Announces Appointment of Karen A. Flynn to Board of Directors
From Quanterix Corporation
Via Business Wire
Quanterix Corporation Releases Operating Results for First Quarter 2022
From Quanterix Corporation
Via Business Wire
Quanterix Corporation to Release First Quarter 2022 Financial Results on May 10, 2022
From Quanterix Corporation
Via Business Wire
Quanterix Granted Breakthrough Device Designation from U.S. FDA for NfL Test for Multiple Sclerosis
From Quanterix Corporation
Via Business Wire
Quanterix’ Simoa® Technology Powers Large, International Comprehensive Reference Range Study Utilizing Serum Neurofilament Light (sNfL) to Assess Disease Activity in Multiple Sclerosis (MS) Patients
From Quanterix Corporation
Via Business Wire
Quanterix Corporation to Release Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022
From Quanterix Corporation
Via Business Wire
Quanterix Receives Funding from the Alzheimer’s Drug Discovery Foundation to Accelerate Alzheimer’s Disease Diagnostic Plasma Test Development
From Quanterix Corporation
Via Business Wire
Quanterix to Participate in the SVB Leerink Global Healthcare Conference
From Quanterix Corporation
Via Business Wire
UK Dementia Research Institute Biomarker Factory Powers Alzheimer’s Disease Breakthroughs with Quanterix Simoa® Technology
From Quanterix Corporation
Via Business Wire
Quanterix’ Simoa® Technology Powers Latest Breakthrough in Epstein-Barr Virus and Multiple Sclerosis
From Quanterix
Via Business Wire
Quanterix Provides Operational and Preliminary Financial Highlights
From Quanterix Corporation
Via Business Wire
Quanterix to Present at 40th Annual J.P. Morgan Healthcare Conference
From Quanterix Corporation
Via Business Wire
Quanterix Recognized as a Fastest-Growing Company in North America on the 2021 Deloitte Technology Fast 500™
From Quanterix Corporation
Via Business Wire
Quanterix’ Simoa® Technology Powers Advances in Alzheimer’s Disease Research Presented at 2021 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
From Quanterix Corporation
Via Business Wire
Quanterix to Participate in the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum
From Quanterix Corporation
Via Business Wire
Quanterix Co-Inventor of Simoa® David Walt Receives Kabiller Prize in Nanoscience and Nanomedicine
From Quanterix Corporation
Via Business Wire
Quanterix Corporation Releases Operating Results for Third Quarter of 2021
From Quanterix
Via Business Wire
Quanterix Corporation to Release Third Quarter 2021 Financial Results on Nov. 4, 2021
From Quanterix
Via Business Wire
Quanterix Granted Breakthrough Device Designation from U.S. FDA for Blood-Based pTau-181 Assay for Alzheimer’s Disease
From Quanterix Corporation
Via Business Wire
Quanterix Hosts Webinar with Leading Pathologist from Emory Medical Laboratories
From Quanterix Corporation
Via Business Wire
Quanterix Receives Label Expansion on Emergency Use Authorization for COVID Antigen Test
From Quanterix Corporation
Via Business Wire
Quanterix to Host Webinar with Leading Pathologist from Emory Medical Laboratories: “COVID-19 Testing in a Residential University Setting: Implementation, Insights, and Learnings”
From Quanterix Corporation
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.